{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:41:19Z","timestamp":1793032879964,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32CA099140"],"award-info":[{"award-number":["T32CA099140"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K12CA076931"],"award-info":[{"award-number":["K12CA076931"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA244711"],"award-info":[{"award-number":["U54CA244711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA244711"],"award-info":[{"award-number":["U54CA244711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA244711"],"award-info":[{"award-number":["U54CA244711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["2001870"],"award-info":[{"award-number":["2001870"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012935","name":"Australian Lions Childhood Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003341","name":"Sarcoma Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016596"],"award-info":[{"award-number":["2016596"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96877-9","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T15:29:12Z","timestamp":1744730952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Tatiana","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Faridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham S.","family":"Bear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyaz ur","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry C. C.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khatuna","family":"Gabunia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Avery D.","family":"Posey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Scholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan A.","family":"Asangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald P.","family":"Linette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz M.","family":"Carreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"96877_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TGP Grunewald","year":"2018","unstructured":"Grunewald, T. G. P. et al. Ewing sarcoma. Nat. Rev. Dis. Primers. 4, 5. https:\/\/doi.org\/10.1038\/s41572-018-0003-x (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"96877_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1200\/JCO.2017.74.7402","volume":"36","author":"AS Pappo","year":"2018","unstructured":"Pappo, A. S., Dirksen, U.  Rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas. J. Clin. Oncol. 36, 168\u2013179. https:\/\/doi.org\/10.1200\/JCO.2017.74.7402 (2018).","journal-title":"J. Clin. Oncol."},{"key":"96877_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/pbc.23040","volume":"57","author":"M Stahl","year":"2011","unstructured":"Stahl, M. et al. Risk of recurrence and survival after relapse in patients with ewing sarcoma. Pediatr. Blood Cancer. 57, 549\u2013553. https:\/\/doi.org\/10.1002\/pbc.23040 (2011).","journal-title":"Pediatr. Blood Cancer"},{"key":"96877_CR4","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar, N. et al. Ewing sarcoma: current management and future approaches through collaboration. J. Clin. Oncol. 33, 3036\u20133046. https:\/\/doi.org\/10.1200\/JCO.2014.59.5256 (2015).","journal-title":"J. Clin. Oncol."},{"key":"96877_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/359162a0","volume":"359","author":"O Delattre","year":"1992","unstructured":"Delattre, O. et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162\u2013165. https:\/\/doi.org\/10.1038\/359162a0 (1992).","journal-title":"Nature"},{"key":"96877_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1056\/NEJM199408043310503","volume":"331","author":"O Delattre","year":"1994","unstructured":"Delattre, O. et al. The ewing family of tumors\u2013a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl. J. Med. 331, 294\u2013299. https:\/\/doi.org\/10.1056\/NEJM199408043310503 (1994).","journal-title":"N Engl. J. Med."},{"key":"96877_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/sj.onc.1200933","volume":"14","author":"M Peter","year":"1997","unstructured":"Peter, M. et al. A new member of the ETS family fused to EWS in ewing tumors. Oncogene 14, 1159\u20131164. https:\/\/doi.org\/10.1038\/sj.onc.1200933 (1997).","journal-title":"Oncogene"},{"key":"96877_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2014.10.004","volume":"26","author":"N Riggi","year":"2014","unstructured":"Riggi, N. et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in ewing sarcoma. Cancer Cell. 26, 668\u2013681. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.004 (2014).","journal-title":"Cancer Cell."},{"key":"96877_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365. https:\/\/doi.org\/10.1126\/science.aar6711 (2018).","journal-title":"Science"},{"key":"96877_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924. https:\/\/doi.org\/10.1200\/JCO.2010.32.2537 (2011).","journal-title":"J. Clin. Oncol."},{"key":"96877_CR11","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 8, 944\u2013957. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1417 (2018).","journal-title":"Cancer Discov"},{"key":"96877_CR12","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460\u20131471. https:\/\/doi.org\/10.1016\/S0140-6736(24)00319-2 (2024).","journal-title":"Lancet"},{"key":"96877_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature25480","volume":"555","author":"SN Grobner","year":"2018","unstructured":"Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321\u2013327. https:\/\/doi.org\/10.1038\/nature25480 (2018).","journal-title":"Nature"},{"key":"96877_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/mpo.1303","volume":"38","author":"R Dagher","year":"2002","unstructured":"Dagher, R. et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med. Pediatr. Oncol. 38, 158\u2013164. https:\/\/doi.org\/10.1002\/mpo.1303 (2002).","journal-title":"Med. Pediatr. Oncol."},{"key":"96877_CR15","doi-asserted-by":"publisher","unstructured":"Mackall, C., Berzofsky, J. & Helman, L. J. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin. Orthop. Relat. Res. 25\u201331. https:\/\/doi.org\/10.1097\/00003086-200004000-00005 (2000).","DOI":"10.1097\/00003086-200004000-00005"},{"key":"96877_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/08880010590935194","volume":"22","author":"F Meyer-Wentrup","year":"2005","unstructured":"Meyer-Wentrup, F., Richter, G. & Burdach, S. Identification of an Immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatr. Hematol. Oncol. 22, 297\u2013308. https:\/\/doi.org\/10.1080\/08880010590935194 (2005).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"96877_CR17","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1158\/1078-0432.CCR-07-4065","volume":"14","author":"CL Mackall","year":"2008","unstructured":"Mackall, C. L. et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin. Cancer Res. 14, 4850\u20134858. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4065 (2008).","journal-title":"Clin. Cancer Res."},{"key":"96877_CR18","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1158\/1078-0432.CCR-12-1985","volume":"18","author":"CH Evans","year":"2012","unstructured":"Evans, C. H. et al. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the ewing sarcoma family of tumors. Clin. Cancer Res. 18, 5341\u20135351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1985 (2012).","journal-title":"Clin. Cancer Res."},{"key":"96877_CR19","doi-asserted-by":"publisher","first-page":"e28313","DOI":"10.1002\/pbc.28313","volume":"67","author":"A Englisch","year":"2020","unstructured":"Englisch, A., Altvater, B., Kailayangiri, S., Hartmann, W. & Rossig, C. VEGFR2 as a target for CAR T cell therapy of ewing sarcoma. Pediatr. Blood Cancer 67, e28313. https:\/\/doi.org\/10.1002\/pbc.28313 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"96877_CR20","doi-asserted-by":"publisher","first-page":"e0133152","DOI":"10.1371\/journal.pone.0133152","volume":"10","author":"X Huang","year":"2015","unstructured":"Huang, X. et al. IGF1R- and ROR1-Specific CAR T cells as a potential therapy for high risk sarcomas. PLoS One 10, e0133152. https:\/\/doi.org\/10.1371\/journal.pone.0133152 (2015).","journal-title":"PLoS One"},{"key":"96877_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","volume":"28","author":"K Hsu","year":"2021","unstructured":"Hsu, K. et al. Chimeric antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours. Cancer Gene Ther. 28, 321\u2013334. https:\/\/doi.org\/10.1038\/s41417-020-00221-4 (2021).","journal-title":"Cancer Gene Ther."},{"key":"96877_CR22","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. et al. CAR T cells targeting B7-H3, a Pan-Cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560\u20132574. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432 (2019).","journal-title":"Clin. Cancer Res."},{"key":"96877_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/bjc.2012.57","volume":"106","author":"S Kailayangiri","year":"2012","unstructured":"Kailayangiri, S. et al. The ganglioside antigen G(D2) is surface-expressed in ewing sarcoma and allows for MHC-independent immune targeting. Br. J. Cancer 106, 1123\u20131133. https:\/\/doi.org\/10.1038\/bjc.2012.57 (2012).","journal-title":"Br. J. Cancer"},{"key":"96877_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/bjc.2013.356","volume":"109","author":"L Liebsch","year":"2013","unstructured":"Liebsch, L. et al. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br. J. Cancer. 109, 658\u2013666. https:\/\/doi.org\/10.1038\/bjc.2013.356 (2013).","journal-title":"Br. J. Cancer"},{"key":"96877_CR25","doi-asserted-by":"publisher","first-page":"110971","DOI":"10.1016\/j.celrep.2022.110971","volume":"39","author":"Q Deng","year":"2022","unstructured":"Deng, Q. et al. Oncofusion-driven de Novo enhancer assembly promotes malignancy in ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1. Cell. Rep. 39, 110971. https:\/\/doi.org\/10.1016\/j.celrep.2022.110971 (2022).","journal-title":"Cell. Rep."},{"key":"96877_CR26","doi-asserted-by":"publisher","first-page":"111761","DOI":"10.1016\/j.celrep.2022.111761","volume":"41","author":"MF Orth","year":"2022","unstructured":"Orth, M. F. et al. Systematic multi-omics cell line profiling uncovers principles of ewing sarcoma fusion oncogene-mediated gene regulation. Cell. Rep. 41, 111761. https:\/\/doi.org\/10.1016\/j.celrep.2022.111761 (2022).","journal-title":"Cell. Rep."},{"key":"96877_CR27","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1523\/JNEUROSCI.0975-20.2021","volume":"41","author":"A Trouillet","year":"2021","unstructured":"Trouillet, A. et al. Loxhd1 mutations cause mechanotransduction defects in cochlear hair cells. J. Neurosci. 41, 3331\u20133343. https:\/\/doi.org\/10.1523\/JNEUROSCI.0975-20.2021 (2021).","journal-title":"J. Neurosci."},{"key":"96877_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ajhg.2009.07.017","volume":"85","author":"N Grillet","year":"2009","unstructured":"Grillet, N. et al. Mutations in LOXHD1, an evolutionarily conserved stereociliary protein, disrupt hair cell function in mice and cause progressive hearing loss in humans. Am. J. Hum. Genet. 85, 328\u2013337. https:\/\/doi.org\/10.1016\/j.ajhg.2009.07.017 (2009).","journal-title":"Am. J. Hum. Genet."},{"key":"96877_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","volume":"32","author":"M Andreatta","year":"2016","unstructured":"Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511\u2013517. https:\/\/doi.org\/10.1093\/bioinformatics\/btv639 (2016).","journal-title":"Bioinformatics"},{"key":"96877_CR30","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","volume":"43","author":"FF Gonzalez-Galarza","year":"2015","unstructured":"Gonzalez-Galarza, F. F. et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res. 43, D784\u2013788. https:\/\/doi.org\/10.1093\/nar\/gku1166 (2015).","journal-title":"Nucleic Acids Res."},{"key":"96877_CR31","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","volume":"14","author":"AW Purcell","year":"2019","unstructured":"Purcell, A. W., Ramarathinam, S. H. & Ternette, N. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat. Protoc. 14, 1687\u20131707. https:\/\/doi.org\/10.1038\/s41596-019-0133-y (2019).","journal-title":"Nat. Protoc."},{"key":"96877_CR32","doi-asserted-by":"publisher","first-page":"12491","DOI":"10.1021\/bi050255v","volume":"44","author":"R Buchli","year":"2005","unstructured":"Buchli, R. et al. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201\u2013a new tool for epitope discovery. Biochemistry 44, 12491\u201312507. https:\/\/doi.org\/10.1021\/bi050255v (2005).","journal-title":"Biochemistry"},{"key":"96877_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-397863-9.00003-1","volume":"109","author":"DA Ferrington","year":"2012","unstructured":"Ferrington, D. A. & Gregerson, D. S. Immunoproteasomes: structure, function, and antigen presentation. Prog Mol. Biol. Transl Sci. 109, 75\u2013112. https:\/\/doi.org\/10.1016\/B978-0-12-397863-9.00003-1 (2012).","journal-title":"Prog Mol. Biol. Transl Sci."},{"key":"96877_CR34","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","volume":"12","author":"AS Bear","year":"2021","unstructured":"Bear, A. S. et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat. Commun. 12, 4365. https:\/\/doi.org\/10.1038\/s41467-021-24562-2 (2021).","journal-title":"Nat. Commun."},{"key":"96877_CR35","doi-asserted-by":"publisher","first-page":"e80060","DOI":"10.1371\/journal.pone.0080060","volume":"8","author":"WA May","year":"2013","unstructured":"May, W. A. et al. Characterization and drug resistance patterns of Ewing\u2019s sarcoma family tumor cell lines. PLoS One. 8, e80060. https:\/\/doi.org\/10.1371\/journal.pone.0080060 (2013).","journal-title":"PLoS One"},{"key":"96877_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/s0165-4608(02)00670-2","volume":"141","author":"A Martinez-Ramirez","year":"2003","unstructured":"Martinez-Ramirez, A. et al. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet. Cytogenet. 141, 138\u2013142. https:\/\/doi.org\/10.1016\/s0165-4608(02)00670-2 (2003).","journal-title":"Cancer Genet. Cytogenet."},{"key":"96877_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0165-4608(86)90001-4","volume":"21","author":"J Whang-Peng","year":"1986","unstructured":"Whang-Peng, J. et al. Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet. Cytogenet. 21, 185\u2013208. https:\/\/doi.org\/10.1016\/0165-4608(86)90001-4 (1986).","journal-title":"Cancer Genet. Cytogenet."},{"key":"96877_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM198408303110907","volume":"311","author":"J Whang-Peng","year":"1984","unstructured":"Whang-Peng, J. et al. Chromosome translocation in peripheral neuroepithelioma. N Engl. J. Med. 311, 584\u2013585. https:\/\/doi.org\/10.1056\/NEJM198408303110907 (1984).","journal-title":"N Engl. J. Med."},{"key":"96877_CR39","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1158\/0008-5472.CAN-04-0377","volume":"64","author":"S Batra","year":"2004","unstructured":"Batra, S., Reynolds, C. P. & Maurer, B. J. Fenretinide cytotoxicity for Ewing\u2019s sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res. 64, 5415\u20135424. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0377 (2004).","journal-title":"Cancer Res."},{"key":"96877_CR40","doi-asserted-by":"publisher","unstructured":"Bendle, G. M. et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 16, 565\u2013570, 561 p following 570. https:\/\/doi.org\/10.1038\/nm.2128 (2010).","DOI":"10.1038\/nm.2128"},{"key":"96877_CR41","doi-asserted-by":"publisher","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367. https:\/\/doi.org\/10.1126\/science.aba7365 (2020).","DOI":"10.1126\/science.aba7365"},{"key":"96877_CR42","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41551-019-0409-0","volume":"3","author":"K Schober","year":"2019","unstructured":"Schober, K. et al. Orthotopic replacement of T-cell receptor alpha- and beta-chains with preservation of near-physiological T-cell function. Nat. Biomed. Eng. 3, 974\u2013984. https:\/\/doi.org\/10.1038\/s41551-019-0409-0 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"96877_CR43","doi-asserted-by":"publisher","unstructured":"Campillo-Davo, D. et al. Rapid assessment of functional avidity of tumor-Specific T cell receptors using an antigen-Presenting tumor cell line electroporated with Full-Length tumor antigen mRNA. Cancers (Basel). 12. https:\/\/doi.org\/10.3390\/cancers12020256 (2020).","DOI":"10.3390\/cancers12020256"},{"key":"96877_CR44","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/jjco\/hyad031","volume":"53","author":"H Aiba","year":"2023","unstructured":"Aiba, H. et al. Clinical characteristics of primary cutaneous and subcutaneous ewing sarcoma. Jpn J. Clin. Oncol. 53, 604\u2013610. https:\/\/doi.org\/10.1093\/jjco\/hyad031 (2023).","journal-title":"Jpn J. Clin. Oncol."},{"key":"96877_CR45","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/pbc.25535","volume":"62","author":"A Di Giannatale","year":"2015","unstructured":"Di Giannatale, A. et al. Primary cutaneous and subcutaneous ewing sarcoma. Pediatr. Blood Cancer. 62, 1555\u20131561. https:\/\/doi.org\/10.1002\/pbc.25535 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"96877_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2121-13-5","volume":"13","author":"I Brunetta","year":"2012","unstructured":"Brunetta, I., Casalotti, S. O., Hart, I. R., Forge, A. & Reynolds, L. E. beta3-integrin is required for differentiation in OC-2 cells derived from mammalian embryonic inner ear. BMC Cell. Biol. 13, 5. https:\/\/doi.org\/10.1186\/1471-2121-13-5 (2012).","journal-title":"BMC Cell. Biol."},{"key":"96877_CR47","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1098\/rspb.1998.0477","volume":"265","author":"MN Rivolta","year":"1998","unstructured":"Rivolta, M. N. et al. Auditory hair cell precursors immortalized from the mammalian inner ear. Proc. Biol. Sci. 265, 1595\u20131603. https:\/\/doi.org\/10.1098\/rspb.1998.0477 (1998).","journal-title":"Proc. Biol. Sci."},{"key":"96877_CR48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature25795","volume":"555","author":"X Ma","year":"2018","unstructured":"Ma, X. et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555, 371\u2013376. https:\/\/doi.org\/10.1038\/nature25795 (2018).","journal-title":"Nature"},{"key":"96877_CR49","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1038\/onc.2016.498","volume":"36","author":"GA Franzetti","year":"2017","unstructured":"Franzetti, G. A. et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation\/migration choices in ewing sarcoma cells. Oncogene 36, 3505\u20133514. https:\/\/doi.org\/10.1038\/onc.2016.498 (2017).","journal-title":"Oncogene"},{"key":"96877_CR50","doi-asserted-by":"publisher","unstructured":"Ding, L. et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173, 305\u2013320 e310. https:\/\/doi.org\/10.1016\/j.cell.2018.03.033 (2018).","DOI":"10.1016\/j.cell.2018.03.033"},{"key":"96877_CR51","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566. https:\/\/doi.org\/10.1038\/nm0596-561 (1996).","journal-title":"Nat. Med."},{"key":"96877_CR52","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl. J. Med. 348, 994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457 (2003).","journal-title":"N Engl. J. Med."},{"key":"96877_CR53","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nm.1983","volume":"15","author":"HV Erkizan","year":"2009","unstructured":"Erkizan, H. V. et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing\u2019s sarcoma. Nat. Med. 15, 750\u2013756. https:\/\/doi.org\/10.1038\/nm.1983 (2009).","journal-title":"Nat. Med."},{"key":"96877_CR54","doi-asserted-by":"publisher","unstructured":"Povedano, J. M. et al. TK216 targets microtubules in Ewing sarcoma cells. Cell Chem Biol 29, 1325\u20131332 e1324. https:\/\/doi.org\/10.1016\/j.chembiol.2022.06.002 (2022).","DOI":"10.1016\/j.chembiol.2022.06.002"},{"key":"96877_CR55","doi-asserted-by":"publisher","first-page":"603278","DOI":"10.3389\/fimmu.2020.603278","volume":"11","author":"SH Du","year":"2020","unstructured":"Du, S. H. et al. Co-Inhibition of the Immunoproteasome subunits LMP2 and LMP7 ameliorates immune thrombocytopenia. Front. Immunol. 11, 603278. https:\/\/doi.org\/10.3389\/fimmu.2020.603278 (2020).","journal-title":"Front. Immunol."},{"key":"96877_CR56","doi-asserted-by":"publisher","unstructured":"Fraga-Silva, T. F. C. et al. Airway epithelial cells and macrophages trigger IL-6-CD95\/CD95L axis and mediate initial immunopathology of COVID-19. iScience 26, 108366. https:\/\/doi.org\/10.1016\/j.isci.2023.108366 (2023).","DOI":"10.1016\/j.isci.2023.108366"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96877-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96877-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96877-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T04:01:07Z","timestamp":1745121667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96877-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96877"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96877-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.B, I.A.A., G.P.L., and B.M.C. are inventors on a patent (63\/516,178) related to the targeting of LOXHD1 for immunotherapy entitled \u201cCompositions and Methods for Targeting LOXHD1-Associated Disease\u201d. All other authors have no competing interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13007"}}